kabutan

Takeda Pharma, 2.1 times Increase in Net Income for The Current Fiscal Year, Dividend Raised by 4 yen

Thu May 8, 2025 3:30 pm JST Earnings

4502 Takeda Pharmaceutical Company Limited 【IFRS】

Earnings Report

Takeda Pharmaceutical Company Limited <4502> [TSE Prime] announced its financial results (based on IFRS) after the market closed on May 8th (15:30). The consolidated net income for the fiscal year ending March 2025 decreased 25.1% from the previous period to 107 billion yen. For the fiscal year ending March 2026, the consolidated net income is expected to expand to 2.1 times to 228 billion yen.

At the same time, the company has decided to increase the dividend this fiscal year to 200 yen, an increase of 4 yen from the previous fiscal year.

In the most recent three-month period, from January to March (4Q), the consolidated net loss expanded to a loss of 103 billion yen (compared to a loss of 3.01 billion yen in the same period last year). The operating profit/loss margin drastically worsened from -1.0% in the same period last year to -7.1%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 4,027,478 490,505 375,090 317,017 204.3 180 May 11, 2023 IFRS
Mar, 2024 4,263,762 214,075 52,791 144,067 92.1 188 May 9, 2024 IFRS
Mar, 2025 4,581,551 342,586 175,084 107,928 68.4 196 May 8, 2025 IFRS
YoY +7.5% +60.0% +231.7% -25.1% -25.8%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 4,590,000 344,000 162,000 118,000 74.8 196 Jan 30, 2025 IFRS
Mar, 2025 Results 4,581,551 342,586 175,084 107,928 68.4 196 May 8, 2025 IFRS
Revision Rate -0.2% -0.4% +8.1% -8.5% -8.6%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 2,384,028 350,576 255,976 187,294 118.9 98 Oct 31, 2024 IFRS
Apr - Sep, 2025 Guidance ー ー ー ー － 100 May 8, 2025 IFRS
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 4,263,762 214,075 52,791 144,067 92.1 188 May 9, 2024 IFRS
Mar, 2025 4,581,551 342,586 175,084 107,928 68.4 196 May 8, 2025 IFRS
Mar, 2026 Guidance 4,530,000 475,000 307,000 228,000 144.3 200 May 8, 2025 IFRS
YoY -1.1% +38.7% +75.3% +111.3% +111.1%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 1,050,869 -10,069 -47,522 -3,018 -1.9 -1.0 May 9, 2024 IFRS
Apr - Jun, 2024 1,207,990 166,329 136,604 95,248 60.7 13.8 Jul 31, 2024 IFRS
Jul - Sep, 2024 1,176,038 184,247 119,372 92,046 58.4 15.7 Oct 31, 2024 IFRS
Oct - Dec, 2024 1,144,124 66,942 26,407 23,789 15.1 5.9 Jan 30, 2025 IFRS
Jan - Mar, 2025 1,053,399 -74,932 -107,299 -103,155 -65.3 -7.1 May 8, 2025 IFRS
YoY +0.2% -644.2% -125.8% -3,318.0% -3,285.5%

Related Articles